Evommune (EVMN) Revenue (2025)
Evommune (EVMN) reported Revenue of $10.0 million for Q3 2025, up 233.33% on a QoQ basis from $3.0 million in Q1 2025.
Evommune (EVMN) has 1 years of Revenue data on file, last reported at $10.0 million in Q3 2025.
- Quarterly Revenue changed N/A year-over-year to $10.0 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $13.0 million (changed N/A YoY) and the FY2025 annual result came in at $13.0 million, up 85.71% from the prior year.
- Revenue rose to $10.0 million in Q3 2025 per EVMN's latest filing, from $3.0 million in the prior quarter.
- Across five years, Revenue topped out at $10.0 million in Q3 2025 and bottomed at $3.0 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Evommune | 782.16 Mn | 570.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 10.00 Mn |
| Mar 31, 2025 | 3.00 Mn |